Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis
Status:
Unknown status
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Angiotensin II has been proposed as a lipid metabolism regulator. It is known that adipocytes
secrete a variety of protein, such as TNFα, plasminogen activator inhibitor (PAI)-1, leptin,
resistin and adiponectin; these proteins have a wide range of biological effects and are
associated with insulin resistance. Adipocytes also produce angiotensinogen and angiotensin
II and a local renin-angiotensin system (RAS) is present in adipose tissue. In overweight or
obese hypertensive normocholesterolemic patients the treatment with AT1-receptor blocker
(Losartan) may have a better effect on hepatic steatosis and visceral fat deposition than the
antihypertensive treatment with calcium channel blocker (amlodipine). Simvastatin will be
added to both groups. The aim of this study is to evaluate the effect of losartan and
simvastatin on ultrasonographic qualitative and quantitative parameters in overweight or
obese hypertensive normocholesterolemic patients with hepatic steatosis.